Burkitt's lymphoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
Kamal Akbar (talk | contribs) No edit summary |
Kamal Akbar (talk | contribs) No edit summary |
||
| Line 10: | Line 10: | ||
* Chemotherapeutic regimens for Burkitt's lymphoma include:<ref name="JacobsonLaCasce2014">{{cite journal|last1=Jacobson|first1=C.|last2=LaCasce|first2=A.|title=How I treat Burkitt lymphoma in adults|journal=Blood|volume=124|issue=19|year=2014|pages=2913–2920|issn=0006-4971|doi=10.1182/blood-2014-06-538504}}</ref> | * Chemotherapeutic regimens for Burkitt's lymphoma include:<ref name="JacobsonLaCasce2014">{{cite journal|last1=Jacobson|first1=C.|last2=LaCasce|first2=A.|title=How I treat Burkitt lymphoma in adults|journal=Blood|volume=124|issue=19|year=2014|pages=2913–2920|issn=0006-4971|doi=10.1182/blood-2014-06-538504}}</ref> | ||
* [[Cyclophosphamide]] {{and}} [[Vincristine]] {{and}} [[Doxorubicin]] {{and}} [[Methotrexate]] (CODOX-M)<ref name="pmid29741758">{{cite journal| author=Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K et al.| title=Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. | journal=Br J Haematol | year= 2018 | volume= 181 | issue= 6 | pages= 782-790 | pmid=29741758 | doi=10.1111/bjh.15262 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29741758 }} </ref> | * [[Cyclophosphamide]] {{and}} [[Vincristine]] {{and}} [[Doxorubicin]] {{and}} [[Methotrexate]] (CODOX-M)<ref name="pmid29741758">{{cite journal| author=Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K et al.| title=Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab. | journal=Br J Haematol | year= 2018 | volume= 181 | issue= 6 | pages= 782-790 | pmid=29741758 | doi=10.1111/bjh.15262 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29741758 }} </ref> | ||
* [[Ifosfamide]] {{and}} [[Mesna]] {{and}} [[Etoposide]] {{and}} [[Cytarabine]] (IVAC) | * [[Ifosfamide]] {{and}} [[Mesna]] {{and}} [[Etoposide]] {{and}} [[Cytarabine]] (IVAC)<ref name="BortzCoutsouvelis2015">{{cite journal|last1=Bortz|first1=H.|last2=Coutsouvelis|first2=J.|last3=Corallo|first3=C. E.|last4=Spencer|first4=A.|last5=Patil|first5=S.|title=Modifying chemotherapeutic management of a patient with Burkitt's lymphoma and pre-existing motor neurone disease|journal=Journal of Clinical Pharmacy and Therapeutics|volume=40|issue=4|year=2015|pages=483–485|issn=02694727|doi=10.1111/jcpt.12293}}</ref> | ||
* [[Cyclophosphamide]] {{and}} [[Vincristine]] {{and}} [[Doxorubicin]] {{and}} [[Dexamethasone]] {{and}} [[Methotrexate]] {{and}} [[Cytarabine]] (Hyper-CVAD) | * [[Cyclophosphamide]] {{and}} [[Vincristine]] {{and}} [[Doxorubicin]] {{and}} [[Dexamethasone]] {{and}} [[Methotrexate]] {{and}} [[Cytarabine]] (Hyper-CVAD) | ||
'''CNS prophylaxis''' | '''CNS prophylaxis''' | ||
Revision as of 21:55, 8 January 2019
|
Burkitt's lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Burkitt's lymphoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Burkitt's lymphoma medical therapy |
|
Risk calculators and risk factors for Burkitt's lymphoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
The predominant therapy for Burkitt's lymphoma is chemotherapy. Adjunctive immunotherapy and stem cell transplantation may be required.
Medical Therapy
The predominant therapy for Burkitt's lymphoma is chemotherapy. Adjunctive immunotherapy and stem cell transplantation may be required.[1]
Chemotherapy
- Chemotherapeutic regimens for Burkitt's lymphoma include:[2]
- Cyclophosphamide AND Vincristine AND Doxorubicin AND Methotrexate (CODOX-M)[3]
- Ifosfamide AND Mesna AND Etoposide AND Cytarabine (IVAC)[4]
- Cyclophosphamide AND Vincristine AND Doxorubicin AND Dexamethasone AND Methotrexate AND Cytarabine (Hyper-CVAD)
CNS prophylaxis
- There is a high risk that Burkitt's lymphoma will spread to the central nervous system (CNS)
- CNS prophylaxis may involve giving intrathecal chemotherapy, high doses of systemic therapy, or both methods may be used
- Methotrexate and Cytarabine are the drugs used most often for CNS prophylaxis[5]
Biological therapy
- Monoclonal antibodies are a type of biological therapy that is effective in treating Burkitt's lymphoma
- Rituximab may be added to each of the above chemotherapy regimens[2]
Stem cell transplant
- A stem cell transplant may be offered to patients with recurrent Burkitt's lymphoma or to patients who relapse after the treatment.[2]
References
- ↑ Burkitt lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/burkitt-lymphoma/?region=on Accessed on September 28, 2015
- ↑ 2.0 2.1 2.2 Jacobson, C.; LaCasce, A. (2014). "How I treat Burkitt lymphoma in adults". Blood. 124 (19): 2913–2920. doi:10.1182/blood-2014-06-538504. ISSN 0006-4971.
- ↑ Zhu KY, Song KW, Connors JM, Leitch H, Barnett MJ, Ramadan K; et al. (2018). "Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab". Br J Haematol. 181 (6): 782–790. doi:10.1111/bjh.15262. PMID 29741758.
- ↑ Bortz, H.; Coutsouvelis, J.; Corallo, C. E.; Spencer, A.; Patil, S. (2015). "Modifying chemotherapeutic management of a patient with Burkitt's lymphoma and pre-existing motor neurone disease". Journal of Clinical Pharmacy and Therapeutics. 40 (4): 483–485. doi:10.1111/jcpt.12293. ISSN 0269-4727.
- ↑ Peñalver FJ, Sancho JM, de la Fuente A, Olave MT, Martín A, Panizo C; et al. (2017). "Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)". Haematologica. 102 (2): 235–245. doi:10.3324/haematol.2016.149120. PMC 5286932. PMID 27846613.